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ABSTRACT 
The pathophysiology of neurodegenerative diseases, such as Alzheimer’s disease 
(AD), remain difficult to ascertain in part because animal models fail to fully recapitulate 
the complex pathophysiology of these diseases. In vitro models of neurodegenerative 
diseases generated with patient derived human induced pluripotent stem cells (hiPSCs) and 
human embryonic stem cells (hESCs) could provide new insight into disease mechanisms. 
Although protocols to differentiate hiPSCs and hESCs to neurons have been established, 
standard practice relies on two dimensional (2D) cell culture systems, which do not 
accurately mimic the complexity and architecture of the in vivo brain microenvironment.   
I have developed protocols to generate 3D cultures of neurons from hiPSCs and 
hESCs, to provide more accurate models of AD. In the first protocol, hiPSC-derived 
neural progenitor cells (hNPCs) are plated in a suspension of Matrigel™ prior to terminal 
differentiation of neurons. In the second protocol, hiPSCs are forced into aggregates 
called embryoid bodies (EBs) in suspension culture and subsequently directed to the 
neural lineage through dual SMAD inhibition. Culture conditions are then changed to 
expand putative hNPC populations and finally differentiated to neuronal spheroids 
through activation of the tyrosine kinase pathway. The gene expression profiles of the 3D 
hiPSC-derived neural cultures were compared to fetal brain RNA. Our analysis has 
revealed that 3D neuronal cultures express high levels of mature pan-neuronal markers 
(e.g. MAP2, β3T) and neural transmitter subtype specific markers. The 3D neuronal 
spheroids also showed signs of neural patterning, similar to that observed during 
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embryonic development. These 3D culture systems should provide a platform to probe 
disease mechanisms of AD and enable to generation of more advanced therapeutics. 
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CHAPTER 1: Introduction 
1.1 Motivation 
Dementia caused by neurodegenerative diseases affects over five million Americans, 
costing $604 billion in care and treatment (Prince et al, 2013). These numbers are 
expected to significantly increase in correlation to the average age of the population. 
(“Brain Disorder: By the Numbers”). Due to the limited understanding of the complex 
pathophysiology of these diseases a curative treatment remains currently out of reach. In 
vitro disease modeling using patient derived human induced pluripotent stem cells 
(hiPSCs) has the potential to elucidate the mechanisms behind these diseases which then 
would allow for the development of a cure. It is therefore imperative any model used 
recapitulates the complex mechanisms inherent to the disease of interest.  
1.2 Neurodegenerative Diseases 
    There are many neurodegenerative diseases affecting numerous regions of the 
peripheral and central nervous system each leading to the degradation and loss of 
function of their respective regions. Among these diseases there are some common 
pathological features, the most prominent being the aggregation of various proteins. 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s 
disease all have the formation of these aggregates (Kopito, 2010).  
 
1.2.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) affects over 5 million Americans, with a new case 
developing every 67 seconds and is the 6th leading cause of death (Prince et al, 2013). AD 
 2 
is associated with memory loss, confusion, agitation, and depression. This makes it a 
tremendous burden both societally and economically for those who must provide support 
(Camille, Conor and Amelia, 2015). There are two main types of AD: early on set AD 
(EOAD) which has a known genetic component and late onset AD (LOAD) which 
remains sporadic. The exact mechanisms driving AD remains unknown. However, there 
are mutations in the amyloid precursor protein (APP), preseinilin-1 (PSEN-1) and 
preseinilin-2 (PSEN-2) that are thought to be key contributing factors in the production of 
beta-amyloid (Aβ) plaques, a pathological hallmark of AD (Tishcha, Esther and Bart, 
2004). The leading hypothesis is that the Aβ plaques then cause the formation of 
neurofibrillary tangles (NFTs), the second pathological hallmark of AD (Oddo, Caccamo 
and Sheperd, 2003; Karran, Mercken, and De Strooper, 2011; Castellani, Rolston and 
Smith 2010). Through the use of in vitro modeling, AD’s etiology has started to be 
identified (Desbordes, Lorenz, 2013). However, there is much more to learn before an 
effective cure can be found. 
1.2.2 Parkinson’s Disease 
Parkinson’s disease (PD) is one of the most prevalent neurodegenerative diseases 
second only to AD (Yarnall, Archibald and Burn, 2012). It is characterized by a 
progressive loss of dopaminergic neurons within the substantia nigra of the mid-brain 
(Wu and Hallett, 2013). Similar to AD, there are a few genetic mutations that have been 
shown to cause PD, but a vast majority are idiopathic. Currently there are 26 distinct 
chromosomal regions associated with PD and six mutations that are monogenic: SNCA, 
LRRK2, Parkin, PINK1, DJ-1, and ATP13A2 (Klein and Westenberger, 2012). Through 
various mechanisms all these mutations lead to the eventual progressive loss of 
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dopaminergic neurons. Here, again, there is the common pathological feature of protein 
aggregation. When specific mutations occur α-synuclein, a protein found in the 
presynaptic terminal, aggregates inside the neuron leading to the formation of Lewy 
bodies (LBs) (Figure 1-2). The formation of LBs cause a disrupution in the cell through 
the displacement of cellular components eventually leading to cell death (Klein and 
Westenberger, 2012; Moore et al, 2005).  
There are several dopaminergic drugs currently available for the symptomatic 
treatment of PD including: pramipexole and ropinirole, which show remarkable results 
(Schapira, 2009). However, there is no curative treatment for PD, and many of these 
drugs can cause dramatic neuropsychiatric symptoms further decreasing a PD patient’s 
standard of living (Aarons, Peisah and Wijeratne, 2012). Apart from pharmacological 
drugs, hPSC therapy replacement has shown promise in the past as a curative treatment to 
PD. Human fetal ventral mesencephalic stem cells were shown to have varying results 
when transplanted into the striata of a PD patient’s brain. Many patients saw a dramatic 
improvement in symptoms (Politis and Lindvall, 2012). Even with these improvements 
and treatments, several questions remain about PD. 
1.2.3 Amyotrophic Lateral Sclerosis 
    Amyotrophic lateral sclerosis (ALS) is pathologically characterized by the progressive 
degeneration of upper and lower motor neurons. While this disease is not as prevalent as 
some other neurodegenerative diseases, only affecting 1 in 100,000, it is very lethal, 
killing those who have it 2-5 years after symptoms appear (Andrews, 2009). Similar to 
the other forms of neurodegenerative diseases, the cause of ALS is mostly sporadic 
(Aggarwal and Shashiraj, 2006). Of the familial cases, there are 16 genetic mutations that 
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are known to play a role in the development of ALS (Pratt, Getzoff and Perry, 2012). In 
the common form of familial ALS, the transcription factor TDP-43 escapes the nuclear 
envelope and forms protein aggregates in the cytoplasm of the affected motor neurons. 
These aggregates are toxic to the neuron leading to eventual cell death (Braak et al, 
2010). The spreading of TDP-43 aggregates through axon terminals to post- and pre-
synaptic neurons and leads to the progressive loss of motor control characterized by this 
disease (Feiler et al, 2015).  In some cases ALS is accompanied by frontotemporal 
degeneration leading to dementia (Nakano, 2001).  
    The progressive loss of motor neurons leads to paralysis that eventually affects the 
diaphragm ending in respiratory failure (Orsini et al, 2015). This disease has a very bleak 
outlook for those who suffer from it. Currently there are no cures for ALS and very few 
palliative treatments available (Ludolph, Brettschneider and Weishaupt, 2012).  
1.2.4 Huntington’s Disease 
    Huntington’s disease (HD) is a neurodegenerative disease characterized by severe 
motor and cognitive deficits between ages 35 to 44 (Frank, 2014).  A trinucleotide repeat 
in the HUNTINGTIN gene leads to a toxic gain-of-function and cytoplasmic aggregate of 
the Huntingtin protein (HTT) (Kowalski et al, 2015). Symptoms of HD fall into two main 
categories: chorea and behavioral changes (Finkbeiner, 2011). HD is known to be nearly 
100% familial with an autosomal dominant inheritance (Novak and Tabrizi, 2010). There 
are currently no cures available for HD and only minimal treatment options available for 
the chorea (Novak and Tabrizi, 2010).  
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1.3 Studying Neurodegenerative Diseases 
    The study of neurodegenerative diseases is vital to the creation of an effective 
treatment. Currently there are many different ways available to study these diseases: (1) 
the use of postmortem studies, (2) animal models, and (3) human induced pluripotent 
stem cells. These models have all helped in the furthering of the understanding of 
neurodegenerative disease pathology and treatments.  
1.3.1 Postmortem Studies 
    Many of the techniques used to study neurodegenerative diseases do not recapitulate 
every aspect of the diseases pathology nor human physiology leaving large gaps in our 
understanding. The use of postmortem studies fills many of these gaps with the analysis 
of diseased individuals shortly after death. Currently these studies are the golden standard 
for examining the pathology of many neurodegenerative diseases (Hartmann, 2004). 
However, even with the benefits learning about human diseases in humans, postmortem 
studies are limited in scope. Many times individuals with these diseases take medications 
that can drastically alter their brain limiting the knowledge gained through this method 
(Pandey and Dwivedi, 2010). Another shortcoming of postmortem studies is their 
inability to reveal disease mechanisms as they unfold (Hartmann, 2004). The latter 
limitation is nearly impossible to circumvent and yet is most critical to the understanding 
of a disease.  
1.3.2 Animal Models 
    Animal models allow for the study of disease mechanisms in ways previously 
unavailable. By using a variety of gene knock-out/in techniques and pharmacological 
agents many neurodegenerative diseases are, in part, able to be modeled (Simmons, 2008; 
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Blandini and Armentero, 2012).  However, animal models have a few inherent limitations 
that prevent the in-depth study of neurodegenerative diseases as they appear in humans.  
For an animal model to recapitulate the disease as it appears in a human its 
genome must be edited in highly specific ways. As stated earlier, many of the causes of 
neurodegenerative diseases remain elusive.  This limits the ability of these diseases to be 
modeled using animals. In many cases the only neurodegenerative diseases being 
investigated in animals are the familial versions with known genetic causes (LaFerla and 
Green, 2012). While there have been attempts to study sporadic causes, it remains to be 
seen as a viable method, limiting its usefulness in the analysis of many disease (Fisher et 
al, 2009). 
When a neurodegenerative disease is modeled in an animal there remain many 
significant short comings. In many cases the disease being modeled does not completely 
recapitulate the disease as it is seen in humans. For example, when AD is modeled in 
mice the formation of NFTs does not take place as it does in humans with AD (LaFrela 
and Green, 2012). For a model to be successful and worth studying it should have 
“similar symptom manifestations, similar underlying biology, [and] similar response to 
clinically effective therapeutic agents” (Mcgonigle and Ruggeri, 2014). However, this is 
not seen in many of the animal models currently being studied.  
1.3.3 Human Induced Pluripotent Stem Cells 
Human induced pluripotent stem cells (hiPSCs) are derived from the reprogramming of 
somatic cells by overexpression of the transcription factors: Klf4, c-Myc, Oct3/4, Sox2 
(Takahashi et al, 2007). Once reprogrammed into hiPSCs they can then be expanded 
indefinitely in culture and differentiated into any somatic cell type. These characteristics 
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allow for many possible uses ranging from drug discovery, cell replacement therapies, 
disease modeling, and many more (figure 1-3). Reprogramming somatic cells from 
sporadic, familial, and healthy individuals and then differentiating those into the diseased 
cell types opens many avenues for the study of these diseases. This process can be used 
to compare genetic differences, mechanism, onset, and progression of the disease 
(Sternecket, Reinhardt and Schöler, 2014). However there is a key limiting factor when 
using hiPSCs, or any cells, in vitro to study diseases: the ability for the in vitro culture to 
recapitulate the complex pathology and pathophysiology inherent to the disease and the 
affected tissue.  
1.3.3.1 In Vitro Two-Dimensional Disease Modeling Systems 
    A common method of studying diseases is differentiating and examining hiPSCs on the 
surface of tissue culture. However, due to the simplistic nature inherent to two-
dimensional (2-D) models many aspects of the native cell environment is loss (Sung et al, 
2013). It has been shown that many key pathological hallmarks of neurodegenerative 
diseases, such as the formation of Aβ plaques and NFTs characteristic of AD, do not 
form in these 2-D culture systems (Benam et al, 2015).  
1.3.3.2 In Vitro Three-Dimensional Organoid Systems  
    To further emulate the complex microenvironments of organs there a focus on three-
dimensional (3-D) systems. 3-D systems have been used for the study of almost every 
organ of the body, showing increased functionality and structure organization over their 
2-D counterparts (Huch and Koo, 2015).  This has led many to hypothesize that 3-D 
models will be able to recapitulate disease pathology in a more accurate manner than 
previously studied (Noble and Burns, 2010). 
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1.4 Overall Goal 
The need for an in vitro system that accurately models neurodegenerative diseases 
is crucial to further the understanding of the complex pathophysiology of these diseases. 
Chapter 2 describes the development of two assays used in the validation of hPSC 
differentiation strategies. Chapter 3 describes the development of 3-DhPSC 
differentiation protocols to allow for the generation of neuronal cells in vitro. Chapter 4 
describes the development of methods and protocols for the generation of ventricular 
cardiomyocytes from hPSCs. Chapter 5 summarizes my research and provides some 
future directions for the protocols developed.  
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Figure 1-1: Comparison of Normal and Diseased Cleavage of Aβ in Alzheimer’s 
Disease 
Alzheimer’s disease is characterized by the formation of amyloid-beta plaques. In healthy 
individuals α-secretase cleaves APP in its transmembrane segment preventing the 
production of Aβ. In AD patients β- and γ-secretase cleave APP at the terminal ends of 
Aβ allowing its release and aggregation in the extracellular space (Patterson et al, 2008). 
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Chapter 2: Development of Assays to Evaluate Neuronal 
Differentiation of hPSCs.  
2.1 Introduction 
 During the differentiation of hPSCs to mature cells, many morphological changes 
take place. It is difficult to analyze cells based purely on morphology, and so a more 
robust, quantifiable method is required. Measuring gene expression through reverse 
transcriptase – quantitative polymerase chain reaction (RT-qPCR) has been proven as one 
of the most useful techniques available to measure gene expression of cells (Marino et al, 
2003). Using this technique, relative changes in gene expression can be compared across 
several conditions.  
For my research RT-qPCR was the main method used in the evaluation of 3-D 
and 2-D hPSC differentiation methods. Here, I have developed a panel of RT-qPCR 
primers that were used for the analysis of the 2-D and 3-D neuronal differentiation 
techniques discussed in chapter 3 (figure 2-1).  
2.2 Primer Design 
 I initially sought to identify genes expressed in the desired differentiated cell 
types (Figure 2-1A). For 2-D and 3-D neuronal differentiation methods I needed to be 
able to examine the changes in gene expression as the hPSCs differentiated into the 
neuronal lineage (figure 2-2). The four primary cell types which required analysis for this 
protocol are:  NPC, general glial, general neural, and neuronal subtype.  
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    In designing primers corresponding to these specific targets, NCBI Primer-BLAST 
was utilized (Figure 2-1B) (Ye et al, 2012). I evaluated three criteria in the design of the 
primers: primer length, product length, and primers spanning exon-exon junctions. 
Primer length is crucial for the specificity of RT-qPCR product amplification. If the 
primer is too long, specificity will be ensured. However, amplification efficiency will 
greatly reduced, therefore skewing the data collected. If the primer is too short, 
specificity will be loss and off target binding will occur. Therefore, I designed primers to 
be 18-24 nucleotides which has been found to be ideal for RT-qPCR (Real-Time PCR 
Handbook). Various methods exist in the detection of RT-qPCR products, for this project 
SYBR Green DNA binding dye was utilized. SYBR Green DNA binding dye is a 
molecule which fluoresces when bound to double stranded DNA (dsDNA), the product of 
RT-qPCR. Product length was designed around SYBR Green DNA binding dye, which 
has an optimal product length of 50-200 bp long (Real-Time PCR Handbook). When 
possible, I designed all primers to span an exon-exon junction. Primers designed in this 
way are unable to bind to genomic DNA that may not have been purified out during RNA 
isolation.  
2.3 Testing and Validation 
 Before the primers can be used for experimental purposes, they must be tested to 
confirm their specificity. This was done by running RT-qPCR with the primers on 
primary tissue samples that have been previously verified to have high expression of the 
target gene (Figure 2-1C). Therefore, these primers were verified against RNA extracted 
from fetal brain tissue weeks 20-26 (CloneTech). Once amplification of the target gene is 
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confirmed, via RT-qPCR, the primers are then validated for target specificity. Two 
methods are used in tandem to confirm this: melt curve and agarose gel electrophoresis 
(Figure 2-1D).  
A melt curve is generated as the last step in RT-qPCR. The concept of a melt 
curve is that the DNA denaturing temperature is highly specific to its length and 
composition. To generate a melt curve, at the end of an RT-qPCR analysis, the 
thermocycler will slowly increase the temperature. As the DNA starts to denature, the 
SYBR Green DNA binding dye will unbind from the DNA, change in fluoresce is then 
measured with respect to time. If the primer is specific, a single melt peak is to be 
expected as all the dsDNA should denature at the same temperature (Figure 2-3A). If, 
however, the primer is not specific, there will be two or more melt peaks (Figure 2-3B).  
It is possible for an off target amplification to occur that is of similar denaturing 
temperature as the target gene. In this instance the melt curve would be obscured by the 
target gene melt curve, and thus have the appearance of only a single product. To further 
confirm the primers are specific, I used agarose gel electrophoresis to separate the 
products amplified during RT-qPCR based on size. If after using this method there is 
only a single band the primer is then considered validated and stored for future use. 
However, if there are two bands then the primer is not specific (Figure 2-4) and must be 
redesigned. This is an iterative process that will be repeated until all the primers are 
completed. 
 I designed primers RT-qPCR primers for the comparison neuronal differentiation 
of hPSCs for in a 2-D and 3-D environment. These primers were tested against RNA 
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isolated from fetal brain and were validated for specificity. The complete list of 
developed primers can be found in appendix A. 
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2Figure 2-1: RT-qPCR Primer Development Process 
The Iterative process required for the design of RT-qPCR primers.  
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3Figure 2-2: Identification of Neuronal Genes  
(A) An examination of the neuronal differentiation protocols revealed three main cell 
types: NPCs, neurons, and glial cells. (B) Genes specific to these cell types were 
researched and the panel of primer targets was established.  
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(A) A single melt peak is present, suggesting a single PCR product. (B) Two distinct 
peaks are present, indicating the primer was not specific, allowing for the 
amplification of two products. X-axis is temperature in Celsius and Y-axis is the 
inverse in the change of fluorescence with respect to time. 
4Figure 2-3: Melt Peaks from RT-qPCR 
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Figure 2-4: Agarose Gel Electrophoresis 
A sample of an agarose gel with the RT-qPCR products for validation. Most channels 
only have a single band indicating the primers were specific. SLC6A4-1, boxed in red, 
has two bands proving it is not specific.  
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CHAPTER 3: Development of 3-D Neuronal Differentiation 
3.1 Abstract 
The pathophysiology of neurodegenerative diseases remains difficult to ascertain 
in part, because current models fail to fully recapitulate the complex pathophysiology 
associated with them. In vitro models of neurodegenerative diseases generated with 
patient derived human induced pluripotent stem cells (hiPSCs) could provide new insight 
into disease mechanisms. Although protocols to differentiate hiPSCs to neurons have 
been established, standard practice relies on two-dimensional (2-D) cell culture systems, 
which do not accurately mimic the complexity and architecture of the in vivo 
microenvironment.  I have developed and evaluated protocols that allows for the three-
dimensional (3-D) neuronal differentiation of hiPSCs which have the potential to be 
further developed into neurodegenerative disease models.  
3.2 Introduction 
 Currently in the United States there are more than 6 million individuals suffering 
from a neurodegenerative disease. The cost of treatment and care for these people is more 
than $600 billion (Brain Disorder by the numbers). For many neurodegenerative diseases 
the pathophysiology is incredibly complex and exceedingly difficult to study. There have 
been many different techniques used to learn about the mechanisms behind these disease: 
postmortem studies, animal models, and two-dimensional (2-D) human induced 
pluripotent stem cell models. However, none of these have shown the ability to 
accurately recapitulate the pathology of these complex and devastating diseases. 
Therefore, there has been a shift into the research of three-dimensional (3-D) organoid 
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models that have proven to provide a more accurate model of a variety of disease (Huch 
et al, 2015). Here, I develop and evaluated protocols that allows for the 3-D neuronal 
differentiation of human pluripotent stem cells (hPSCs). Specifically, I evaluated the 
following protocols: using Matrigel™ as a support structure for neuronal differentiation, 
with both (1) thick and (2) thin gel structures, (3) and performing neuronal differentiation 
on 3-D cell aggregates form human neuronal spheroids (hNS).  
3.3 Materials and Methods 
3.3.1 Medias 
3.3.1.1 Essential 8 (E8) 
 E8 is a xeno-free, defined maintenance media used for the long term expansion of 
hPSCs. DMEM/F12 is used as a base supplemented with: sodium bicarbonate, L-
Ascorbic acid-2-phosphate, sodium selenite, transferring, insulin, FGF2, TGFB, and 
penicillin streptomycin.  
3.3.1.2 Neural Media 
 Neural base media (NBM) is composed of DMEM/F12 supplemented with 0.5% 
N2, 0.5% B27 and 1% GlutaMAX. This is used as a base media for the following 
neuronal differentiation media.  
Neural induction media (NIM): 200 ng/ml Noggin (NOG) and 0.5 uM 
Dorsomorphin (DM) 
Neural expansion media (NEM): 20 ng/ml basic fibroblast growth factor (bFGF) 
and 20 ng/ml epidermal growth factor (EGF)  
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Neural differentiation media (NDM): 20 ng/ml brain-derived neurotrophic factor 
(BDNF), 20 ng/ml glial derived neurotrophic factor (GDNF), 0.5 uM dibutyrl-
cAMP (db-cAMP), and 20 ng/ml DAPT, a Notch inhibitor. 
Human neuronal spheroid media (hNSM): 20 ng/ml brain-derived neurotrophic 
factor (BDNF), 20 ng/ml glial derived neurotrophic factor (GDNF) 
3.3.2 Maintenance of Neural Progenitor Cells and HPSCs  
HPSCs were expanded and maintained in an undifferentiated state at standard 
conditions (37oC, 5% CO2) on Matrigel™ coated polystyrene tissue culture plates. E8 
media was changed every day. Cells were allowed to grow till 70-80% confluency and 
were passed at 2 x 104 cells/cm2, every three to four days as required.  
Neural progenitor cells (NPCs) were expanded and maintained on poly-L-
ornithine and Laminin (PLO/LN) coated plates. They were cultured in NEM which was 
changed on days one and three. Once cells were 100% confluent they were passaged to a 
new PLO/LN coated plate at 1.2 x 104 cells/cm2, every three to four days as required. 
3.3.3 2-D Neuronal Differentiation of hPSCs  
 Figure 3-1 shows the outline of the 2-D neuronal differentiation protocol. HPSCs 
were grown on Matrigel™ and dissociated using Accutase once they reached 80% 
confluency. They were then suspended in 3 ml NIM and 5 mM ROCKi in a 6-well ultra-
low adhesion plate at a concentration of 2 x 106 per well and placed on a shaker at 95 
RPM in the incubator. After one day cells aggregated forming embryoid bodies (EBs). 
Half the media was changed each day. After five days, EBs were transferred to 
Matrigel™ coated plates and allowed to adhere for two days in NIM. After two days the 
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media was changed daily with NIM. After seven days neural rosettes that had formed 
were dissociated using Accutase and re-plated on PLO/LN coated plates in NEM and 5 
uM ROCKi. After three passages only NPCs were present and were maintained or 
expanded as needed. To further differentiate NPCs to neurons they were grown to 100% 
confluency and then media was replaced with NDM. Half of the NDM was then changed 
daily for two weeks, at which time cells were analyzed using immunofluorescence (IF) 
and RT-qPCR (Brafman, 2014).   
3.3.4 3-D Differentiation of hESCs to Neurons 
3.3.4.1 Thick 3-D Matrigel™ culturing 
 NPCs were maintained on PLO/LN coated plates, in standard conditions until 
they were 100% confluent. Cells were incubated in Accutase for 6-7 minutes and were 
then suspended in cold NDM and counted. The cells were then diluted to a 1:1 
concentration of Matrigel™ and cell/NDM mixture for a final concentration of 8 x 106 
cells/ml, along with 5 uM of ROCKi and vortexed for 30 seconds. A 0.4 um pore 
diameter ThinCert (Greiner Bio-One) was placed into a well and 300ul of the 
Matrigel™/cell/NDM mixture was added into the ThinCert (figure 3-2B). The plate was 
then incubated at standard conditions over night. The following day a gel was visible to 
the naked eye, and multiple cell planes were confirmed using a microscope. 1.4 ml of 
NDM was added to the side of the well and 0.1 ml of NDM was gently added to the 
inside of the ThinCert. Half of the media was changed every day.  
3.3.4.2 Thin 3-D Matrigel™ culturing 
 NPCs were maintained on PLO/LN coated plates in standard conditions until they 
were 100% confluent. Cells were incubated in Accutase for 6-7 minutes and were then 
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suspended in cold NDM and counted. The cells were then diluted into a 1:1 concentration 
of Matrigel™ and cell/NDM mixture for a final concentration of 8 x 106 cells/ml. Five 
times this volume of cold NDM was added to the solution along with 5 uM ROCKi and 
vortexed for 30 seconds. After, 100 ul of the Matrigel™/cell mixture was added to a 96-
well plate and incubated over night at standard conditions (Figure 3-2A). The following 
day 200 ul of warm NDM was added to each well. Half the media was changed every day 
for the next four to six weeks. Extreme care was taken when removing and adding media 
as the gels were very fragile and peeled off the plate easily. 
3.3.4.3 Human Neuronal Spheroid Differentiation  
 HPSCs were cultured on Matrigel™ until they reached 70-80% confluency where 
they were then dissociated by incubation in Accutase for 6-7 minutes. 2.0 x 106 cells 
were then suspended in ultra-low adherent tissue culture plates on a shaker (95 RPM) in 
standard conditions in 3ml of NIM and 5uM ROCKi. Half the media was changed every 
day for five days. The cells aggregated together on the first day and formed EBs. In this 
state the cells began differentiating down the ectodermal germ layer (Chambers et al, 
2009). On day six the EBs were kept in the low adherent culture conditions and NIM was 
exchanged for NEM. The cells were maintained in this media for 18 days, with half the 
NEM changed daily. During this time the cells were proliferative and many of the EBs 
grew dramatically in size. On day 25, NEM was exchanged for hNSM. This media was 
used for the next 18 days with half the media changed daily. At this time the cells 
differentiated into neurons and glial cells comprising the human neuronal spheroids. On 
day 43 hNSM was exchanged for NBM and media was changed every 2-3 days as it 
turned yellow, due low pH in the presence of phenol red.   
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3.3.5 RT-qPCR 
 RT-qPCR was performed at specific time points to analyze progress of neuronal 
differentiation. For the 2-D cultures, cells were dissociated by incubation in Accutase for 
5-7 minutes. They were then pelleted and stored at -80oC. For the Matrigel™ thick 3-D 
cultures the gels were removed from the inserts by slitting the bottom and centrifuging 
for 5 minutes in a 15 ml conical tube and stored at -80oC. The thin 3-D gels were 
removed by incubating in Accutase for 6-7 minutes and then were removed by pipetting 
the Accutase quickly up and down in the well. They were then pelleted and stored at -
80oC. RNA was isolated with a NucleoSpin™RNA kit (Macherey-Nagel) and cDNA 
synthesized using iScript RT Supermix (Biorad). RT-qPCR was done with iTaq 
Universal SYBR Green SMX 500 (Biorad) to form the master mix. RT-qPCR primers 
developed in chapter 3 were used. The Bio-Rad CFX384 real-time PCR detection system 
was used to run the RT-qPCR. Results were analyzed from the cycle threshold (CT) 
values using delta-delta CT method. 
3.3.6 Immunofluorescence 
 Immunofluorescence was performed on the samples to determine the structure 
and protein expression of the neurons. For the 2-D cultures and thin 3-D on days 14 and 
28, respectively, the cultures were washed three times with Dulbecco’s phosphate-
buffered saline (DPBS). Fixation buffer (BD Biosciences) was added to the wells for 15 
minutes. The buffer was removed and the cultures were washed again with DPBS. Perm 
Buffer III (BD Biosciences) was then added to the wells for 15 minutes. The cells were 
washed again with DPBS and primary antibodies were add along with Hoechst and were 
incubated wrapped in foil at 4oC overnight. The cells were washed again with DPBS and 
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the secondary fluorescent antibody was added for 1 hour and incubated at 37oC. A final 
wash was done and cultures were wrapped in foil and stored at 4oC.  
3.3.7 Statistical Analysis 
 All values are shown as mean ± standard deviation. A p-value of <0.05 was 
considered statistically significant.  
3.4 Results and Discussion 
A 2-D in vitro environment is unable to recapitulate many facets of the cell 
architecture, and therefore cannot be used to study many neurodegenerative diseases. To 
this end, three 3-D protocols were developed and tested to allow for neuronal 
differentiation of hPSCs which could improve in vitro disease models: Matrigel™ gels, 
thick and thin, and suspension culture of hNS.  
3.4.1 Thick and Thin 3-D Matrigel™ Culturing 
 To examine the viability as a 3-D neuronal differentiation system, NPCs were 
differentiated with NDM in Matrigel™.  Matrigel’s™ capability to solidify into 3-D gels 
and its ability to recapitulate more of the in vivo microenvironment, through the presence 
of extracellular matrix proteins and growth factors, makes it ideal for 3-D differentiation 
of hPSCs. 
 Well inserts, ThinCerts, were used for the thick 3-D gel neuronal differentiation 
of NPCs (Figure 3-2B). In a standard, in vitro environment, a cell’s metabolic activity 
decreases the pH of their media below normal physiologic conditions. Phenol red is a pH 
indicator that is commonly added to media to indicate pH level by a change in media 
color. Over the course of one week, the media added to the thick 3-D gels no long 
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changed color, indicating little to no cell metabolic activity. We hypothesized that poor 
gas and nutrient diffusion through the thick 3-D Matrigel™ cultures resulted in high 
levels of cell death. This is further confirmed when an LDH assay was run on the thick 3-
D samples. To find maximum LDH release, 100 ul of Triton X-100 (20% Triton X-100, 
90% DPBS) was added to the ThinCert to lyse the cells and allowed to incubate for two 
hours. Media samples were then taken from inside of the ThinCert and the surrounding 
media. The LDH assay kit was then used to measure relative fluoresce. Relative 
fluorescence from inside the ThinCert was significantly higher than fluorescence from 
the surrounding media. In fact, fluorescence from the surrounding media was equivalent 
to that of the control, fresh media (Figure 3-3B). This discrepancy between LDH present 
inside and surrounding the ThinCert demonstrates the low diffusion ability of the thick 3-
D gels.   
Due to low diffusion, we developed a protocol in which thinner 3-D gels were 
employed (Figure 3-2A). However, the thin gels proved highly susceptible to mechanical 
disruption due to media changes, resulting in the loss of a significant amount of cultures 
(Figure 3-3A). The LDH assay revealed a significant amount of cell death over the first 
few days in culture, demonstrating that by day three a majority of cells had died (Figure 
3-3D). IF staining of B3T, a general neuron marker, showed no neurite structures present 
in culture, illustrating the inability of thin 3-D gels to differentiate hPSCs to neuronal 
cells (Figure 3-1C). We hypothesize, that while cells still remained in the culture for the 
period of neuronal differentiation, they were dead and embedded in the Matrigel™. 
A common issue with differentiation protocols, is the heterogeneity of available 
cell lines and their variable response to the same stimuli (Abbot et al, 2006). To this end, 
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three different hPSCs lines were tried: two hESCs and one hiPSCs (Figure 3-4A, B). 
Trials with the three cell lines gave rise to similar results with no neurite morphology and 
high sensitivity to mechanical disruption. Additionally two cell density gradients (1.5 x 
105 and 1.0 x 105cells per well) (Figure 3-4A, B) and three Matrigel™ concentration 
(1:10, 1:15, 1:20) (data not shown) were tried. These two variables showed no 
improvement in culture survivability for both thick and thin gels. 
RT-qPCR was attempted to compare gene expression of the multiple techniques. 
Matrigel is composed of a high quantity of RNA and proteins that are difficult to remove 
during RNA isolation. This resulted in high impurity of the samples during RNA 
isolation, preventing their analysis using RT-qPCR. Additionally, cryofixation was 
needed to perform IF on the thick 3-D samples. During this process, the gel was not 
structurally stable, forming a semi-round bead when removed from the ThinCert, 
preventing the investigation of its internal structure. Due to our inability to differentiate 
the hPSCs to neuronal cells, along with the difficulty experienced in analysis of the 
samples, the 3-D Matrigel™ method was abandoned.  
3.2 Human Neuronal Spheroids 
Nest, I developed and evaluated a suspension culture method for 3-D neuronal 
differentiation of hPSCs. The development of these human neuronal spheroids (hNS) 
took several months of experimentation with a variety of different factors including: 
hPSC line and cell density (Figure 3-5). Through this experimentation, I determined 
HUES9 TOP-GFP at 1.0 x 106 cells per well was the best cell line and density based cell 
survivability and morphology of the hNS compared to that of the other cell lines 
examined.  
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3.2.1 Gene Expression 
The protocol for hNS differentiation is shown in figure 3-6A.  RT-qPCR was used 
to measure gene expression during neuronal differentiation. Differentiation of NPCs was 
assessed by IF and RT-qPCR for NPC markers SOX1, SOX2, NESTIN (Figure 3-6B). By 
day 30, IF indicated the presence of NESTIN throughout hNS, confirming differentiation 
to NPCs from hPSCs. The Neuronal markers MAPT, B3T, and NCAM1 were examined 
using RT-qPCR. Figure 3-7 shows an increase in the neuronal maturity marker MAPT 
compared to hiPSCs and similar levels of expression of all three markers as compared to 
the 2-D protocol by day 52 of the hNS differentiation. At day 52, neuronal subtypes were 
examined, demonstrating the presence of a heterogeneous neuronal population via RT-
qPCR (Figure 3-8). Expression of glial cell markers were analyzed signifying the 
presence of cells with astroglial characteristics (Figure 3-9). Together, these results 
confirm that the hNS are differentiating into a heterogeneous population of neuronal cells 
and are currently as effective in differentiation as the 2-D protocol.  
3.3 Conclusion 
 Multiple neuronal differentiation protocols were developed and tested in order to 
provide a 3-D system in which neurodegenerative diseases can be studied. We found that 
hPSCs suspended in a Matrigel™ gel did was as a viable means for neuronal 
differentiate. However, using a suspension culture technique to form hNS in suspension 
culture proved effective in neuronal differentiation of hPSCs in a 3-D environment. RT-
qPCR results have shown that this method is equivalent to standard 2-D methods. I 
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hypothesize that further optimization of this protocol would allow for increased 
efficiency and maturity of the neuronal differentiation. 
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5Figure 3-1: Protocol for Generation of NPCs and 2-D Neuronal Differentiation  
Protocol for 2-D differentiation of hPSC to NPCs and Neuronal cells.  
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6Figure 3-2: Illustration of Thick and Thin 3-D Matrigel™ Methods 
(A) An illustration of the NPCs suspended in a thin 3-D Matrigel™ gel at the bottom of a 
well. (B) An illustration of NPCs and Matrigel™ suspended in a ThinCert for the thick 3-
D neuronal differentiation.  
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Figure 3-3: 3-D Matrigel™ Cultures Differentiation and Survivability 
(A) Thin 3-D gels were highly susceptible to peeling when media was changed. Large 
gaps can be seen where Matrigel™ gel has detached from the plate. (B) LDH assay 
measuring relative fluorescence taken from media around the ThinCert compared to 
media taken from inside the ThinCert two hours after cell lysis.  Relative fluorescence 
from fresh media is comparable to media taken from around the ThinCert two hours after 
the cells being lysed (mean ± SD of two biological samples). *P<0.05 using student’s t-
test). (C) IF staining of day 28 thin 3-D Matrigel™ neuronal differentiation, nuclear 
Hoechst (blue) and B3T (green) stained. No intact nuclei or B3T structures were 
observed.  (D) Percent of cells that have died each day as determined by LDH assay 
showing increased cell death over consecutive days.  
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7Figure 3-4: Optimization of Cell Line and Cell Density for Thin 3-D Matrigel™ 
Three cell lines and two densities were tested for the thin 3-D protocol. (A) With a high 
cell density of 1.5 x 105 cells per well, there was increased cell death by day seven as 
compared to the low density (B). The lower density condition displayed higher cells 
survivability for a longer period of time. However, by day ten the same peeling was 
present at low density as the high (data not shown).  
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8Figure 3-5: Optimization of Cell Line and Cell Density for HNS 
(A) By day seven of hNS protocol cell death was extremely prevalent when using 
RIPSCs line. (B) HNS protocol for the HES3 cell line showed high variability when 
using HES3 cells, with many atypical EB morphologies. (C) Day ten of hNS protocol 
using HUES9 TOP-GFP demonstrated less morphological variance as well as 
comparatively minimal cell death. (D) HUES9 TOP-GFP was further optimized to a 
density of 1 x 106 cells per well which demonstrated increased survivability of EBs.  
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9Figure 3-6: Time Course and IF of NPC Genes During hNS Differentiation 
(A) Schematic of protocol for hNS differentiation. (B) Gene expression time course of 
NPC markers SOX2, SOX1, and NESTIN was determined by RT-qPCR (mean ± SD of 
two biological samples, normalized to 18s and relative to hiPSCs). *P < 0.05. Using 
ANOVA no statistical significant differences were present. This is compared to the 2-D 
protocol (2-D) 14 days after differentiation as well as RNA isolated from fetal brains 
(FB) 20-26 weeks old. (C) IF of hNS day 30, hoechst nuclear stain (blue), NPC marker 
NESTIN (red), and endogenous WNT (green) (scale bar = 200 um). 
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10Figure 3-7: Time Course of Neuronal Specific Genes  
Time course of gene expression for neuronal specific genes MAPT, B3T, and NCAM1 
were determined by RT-qPCR (mean ± SD of two biological samples, normalized to 18s 
and relative to hiPSCs). *P < 0.05. This is compared to the 2-D protocol (2-D) 14 days 
after differentiation as well as RNA isolated from fetal brains (FB) 20-26 weeks old. 
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11Figure 3-8: Comparison of Neuronal Subtype Gene Expression of HNS, 2-D, and FB 
Measurement of neuronal subtype genes as measured by RT-qPCR (mean ± SD of two 
biological samples, normalized to 18s and relative to hiPSCs) for day 14 2-D, day 52 
hNS, and weeks 20-26 fetal brain (FB). *P < 0.05 as determined by student’s t-test. 
Similar levels of expression were found in most neuronal subtype genes for the hNS and 
2-D protocols.  
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12Figure 3-9: Comparison of Glial Cell Gene Expression of hNS, 2-D, and FB 
Measurement of glial cell genes as measured by RT-qPCR (mean ± SD of two biological 
samples, normalized to 18s and relative to hiPSCs) for day 14 2-D, day 52 hNS, and 
weeks 20-26 fetal brain (FB). *P < 0.05 as determined by student’s t-test. Similar levels 
of expression were found in most glial cell genes for the hNS and 2-D protocols.  
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Chapter 4: Long Term Differentiation of Human Ventricular 
Cardiomyocytes 
4.1 Abstract 
 Myocardial infarction (MI) is one of the leading causes of death in the United 
States. However, an effective treatment has yet to be developed that will allow for the 
repair of the damaged tissue leading to drastic loss in the heart efficiency. HPSC 
replacement therapies are thought to be a promising technique to allow for the 
regeneration of this damaged tissue. The development of a protocol that will allow for the 
scalable and efficient differentiation of hPSCs to ventricular cardiomyocytes (VCMs), the 
key damaged cell type of the heart, remains elusive. Here, I demonstrate that allowing 
VCMs to develop from cardiomyocytes through by temporal factors is an ineffective 
means of VCM differentiation.  
4.2 Introduction 
 Cardiovascular disease currently affects more than 83.6 million Americans and is 
the leading cause of death in the United States. Out of those, 7.6 million have 
experienced a myocardial infarction (MI) (Go et al, 2013). An MI can cause the death of 
over 1 billion ventricular cardiomyocytes (VCMs), severally hampering the hearts ability 
to pump blood (Murry et al, 2006). The heart’s capacity to repair itself is extremely 
limited, leading to the formation of scar tissue and loss of function of the cardiomyocyte 
(CM) tissue. To address this problem many groups are looking at hPSCs replacement 
therapies to regenerate the damaged muscle of the heart (Mariann et al, 2016). Directing 
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hPSCs to VCMs currently remains an inefficient process (Vincent et al, 2009). Here, I 
demonstrate that allowing VCMs to develop from cardiomyocytes through by temporal 
factors is an ineffective means of VCM differentiation. 
4.3 Materials and Methods 
4.3.1 Cell Culturing 
 A hESC ventricular report line was chosen for this experiment. MLC2V, a 
ventricular specific marker, was stably transfected with a GFP reporter allowing for the 
expression of GFP when MLC2V actively being expressed (Figure 4-1). GFP expression 
allowed for the visualization and counting via flow cytometry of VCMs of the time 
course of the experiment.   
MLC2V-GFP were expanded and maintained in an undifferentiated state at 
standard conditions on Geltrex coated polystyrene tissue culture plates. Fresh E8 media 
was exchanged every day. Cells were allowed to grow till 70-80% confluent and were 
passed at 2 x 104 cells/cm2, every three to four days as required.  
4.3.2 Differentiation of hESCs to Cardiomyocytes 
 Once MLC2V reached 70-80% confluency media was changed to RPMI/B27 
without insulin supplemented with 12 uM CHIR99021, a GSK-3 inhibitor that activates 
WNT signaling. Media was changed to RPMI/B27 without insulin 24 hours later. After 
48 hours the media was exchanged for RPMI/B27 without insulin supplemented with 5 
uM IWP2, a PORCN inhibitor leading to the inhibition of endogenous WNT processing 
and secretion. After 48 hours, media was exchanged for RPMI/B27 without insulin and 
then fresh RPMI/B27 without insulin was every three days. 
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4.3.3 Flow Cytometry 
 Flow cytometry was performed to analyze the percent of cells that were GFP+. 
Every five days, cells were dissociated to single cell using typeLE (Life Technologies) 
and filtered through a 40 um cell strainer (Bio express) to remove cells clumps. They 
were then washed with FACS stain buffer (BD Bioscience) and run counted using a flow 
cytometer.  
4.3.4 Statistical Analysis 
 All values are shown as mean ± standard deviation. A p-value of <0.05 was 
considered statistically significant.  
4.4 Results and Discussion 
 The protocol for cardiomyocyte differentiation is extremely sensitive to cell 
density. Before a time course could be run several density gradients were performed 
(50%, 60%, 70%, 80, 90%, and 100% confluency) to determine optimal starting cell 
density (data not shown). Ideal differentiation starting confluency was determined to be 
between 70-80%.  
Using the MLC2V-GFP reporter line, VCMs were measured using flow 
cytometry over the course of 80 days (Figure 4-3). Beating cardiomyocytes were present 
by day 8 in a majority of well with GFP expression starting on day 20 in a small 
population of cells (data not shown). There was a steady increase in GFP+ cells between 
days 20 to 30. However, the GFP+ expression leveled off with no significant increases 
from days 35 to 80. This demonstrates that there is a small temporal element in the 
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differentiation of hPSCs to VCMs. A majority of the cells remained either atrial or nodal 
cardiomyocytes.  
4.5 Conclusion 
 In order for a heart failure cell replacement therapy to be effective it must have an 
extremely high efficiency in the differentiation of VCMs. The method tried here shows a 
slight increase in the generation of VCMs by allowing the CMs to mature over time. 
However, this increase is not efficient enough to allow for the cell quantities needed for a 
cell replacement therapy. Many groups have found high proficient methods of generating 
VCMs through the use of small molecules during the differentiation process (Karakikes 
et al, 2014). It is possible that through a combination of small molecule-mediated 
differentiation with the addition of the temporal factors highly efficient VCMs methods 
can be developed.  
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13Figure 4-1: MLC2V GFP Reporter  
The GFP reporter is directly downstream of the MLC2V gene. GFP is then expressed 
simultaneously with MLC2V when a ventricular transcription factor binds to the 
promoter region.  
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14Figure 4-2: Ventricular Cardiomyocyte Differentiation Protocol 
Protocol for cardiomyocyte differentiation. Over the course of seven days hPSCs are 
differentiated into cardiomyocytes (CM). These are then allowed to differentiate further 
into the three cell types of the heart: ventricular CMs, atrial CMs, and nodal CMs. This 
further differentiation us not directed by exogenous addition of small molecules or 
growth factors.  
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15Figure 4-3: GFP Expression during Ventricular Cardiomyocyte Differentiation 
Flow Cytometry for percent of GFP+ cells that expressed the VCM marker, MCL2V. *P 
<0.05. 
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Chapter 5: Conclusions and Future Prospectives  
5.1 Abstract 
 Throughout the course of the master’s program I have developed and tested 
several differentiation methods as well as designed a panel of RT-qPCR primers for the 
analysis of the neuronal differentiation protocols. The 3-D neuronal protocols can be split 
into two categories: Matrigel™ and suspension. The 3-D Matrigel™ methods, thick and 
thin gels, proved as an unreliable method for neuronal differentiation. While still 
preliminary, the suspension culture neuronal differentiation of hNS demonstrated 
equivalent results of neuronal differentiation as standard 2-D methods, as analyzed using 
the panel of RT-qPCR primers. The cardiomyocyte differentiation showed limited 
capabilities in the production of VCMs over the course of 80 days. Here, I speculate as to 
the future of these projects and their potential use in their respective fields.  
5.2 Developing A 3-D Neurodegenerative Disease In Vitro Model  
 To gain a greater understanding of neurodegenerative diseases, an in vitro model 
is needed that is able to recapitulate the many aspects of the disease pathophysiology. 
Therefore, the motivation for the hNS project is to develop a model which possess those 
capabilities. Currently, this project requires further optimization and analysis before it 
can be used as an effective method for neurodegenerative disease modeling. Once this 
has been achieved, the hNS can then be differentiated, through the use of neuronal 
patterning, to the many distinct neuronal subtypes (Moya et al, 2014). This would 
potentially allow for the study of diseases affecting the diverse areas of the brain.  
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 The panel of RT-qPCR primers designed is a general panel useful in the analysis 
of unpatterned neuronal differentiation. To continue to be of use for the hNS project the 
panel needs to be expanded upon to include a larger variety of neuronal subtype specific 
primers. This would then allow for the examination of the patterned hNS. Once 
development and analysis of the hNS is completed, the in-depth study of many 
neurodegenerative diseases becomes possible.  
5.3 Ventricular Cardiomyocyte Differentiation 
 Since ventricular muscle is the most detrimental to patient health when lost in a 
MI, it is critical that a protocol be developed for the efficient generation of VCMs for 
future cell replacement therapies. The method developed here demonstrated a temporal 
factor in the differentiation of VCMs. However, this factor is small, with only 2-6% of 
total cells expressing the ventricular marker, MLC2V. Currently, many groups are 
looking at the use of small molecules and growth factors to force the differentiation of 
hPSCs to VCMs (Karakikes et al, 2014). This is proving effective in the generation of a 
nearly pure population of VCMs with the addition of the temporal element.  
5.4 Conclusion  
 The development of 3-D in vitro disease models will have significant impact in 
the study of neurodegenerative diseases by allowing for the recapitulation of the in-depth 
examination of the disease mechanisms. Furthermore, hNS could be used for the high-
throughput drug screening by pharmaceutical companies in their attempt to find a 
treatment of these diseases. Here, I have emphasized the need for further optimization of 
the hNS protocol as well as the future uses of this system. It is my desire that this 
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protocol be used in the advancement of human knowledge and treatment of 
neurodegenerative diseases.  
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APPENDIX A 
TABLE 1: FORWARD AND REVERSE PRIMERS USED FOR RT-QPCR 
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Gene Forward Reverse 
Product Length 
(bP) 
NPC       
SOX1 AATACTGGAGACGAACGCCG CCCTCGAGCAAAGAAAACGC 182 
SOX2 GCGGAAAACCAAGACGCTCA TCATGCTGTAGCTGCCGTTG 123 
NESTIN CGCACCTCAAGATGTCCCTC CAGCTTGGGGTCCTGAAAGC 128 
Neuronal       
B3T       
MAPT AGGGGGCTGATGGTAAAACG TTGCTTAGTCGCAGAGCTGG 140 
NCAM1 GATGCGACCATCCACCTCAA CCAGAGTCTTTTCTTCGCTGC 178 
Neuronal 
Subtype 
    
  
ACHE CACAGGGGATCCCAATGAGC CGTCGAGCGTGTCGGTG 18 
SLC6A4 AGAATTTTACACGCGCCACG GAGGTCTTGACGCCTTTCCA   
EAAT3 TGGTGCTAGGCATTACCACA CCGGATACGTTGGAATCCAGT 172 
GABRA1 TGCGGATTTCGTCCTGACTT AATCTGCAGCTCTGAATTGTGC 194 
GRIN2A AGCCTCCGGCTGGGATAG CCACTGACGGTCCCTGTAG 191 
Glial       
EAAT2 ATGGCATCAACAGAGGGTGC CTCCCAGGATGACACCAAACA 172 
GFAP AACCTGCAGATTCGAGGGGG GGCGGCGTTCCATTTACAATC 128 
MBP CTGTGCAACATGTACAAGGACTC GGGACAGTCCTCTCCCCTTT 175 
S100B GGGAGACAAGCACAAGCTGA CCTCCTGCTCTTTGATTTCCTCTA 91 
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APPENDIX B 
TABLE 2: NPC, NEURAL, AND GLIAL RT-QPCR PRIMERS DESIGNED AND 
VALIDATED 
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Gene 
Abbreviation Gene Name Summary 
SOX1 SRY- Box 1 Pluripotency marker 
SOX2 SRY- Box 2 NPC marker 
NESTIN Nestin Neuron intermediate filament protein 
B3T Tubulin, Beta 3 Class III Neuron microtubule protein 
MAP2 Microtubule-Associated Protein 2 Neuron microtubule assembly 
MAPT Microtubule-Associated Protein Tau 
Neuron microtubule assembly and 
stability 
ACHE Acetylcholinesterase Hydrolyzes ACH in brain 
SLC6A4 Solute Carrier Family 6, Member 4 
Serotonin neurotransmitter 
membrane protein 
EAAT3 Solute Carrier Family 1, Member 1 
Glutamate neurotransmitter 
membrane protein 
GABRA1 
Gamma-Aminobutyric Acid A Receptor, 
Alpha 1 GABA neurotransmitter receptor 
GRIN2A 
Glutamate Receptor, Innotropic, N0Methyl 
D-Asparate 2A Glutamate-gated ion channel  
NCAM1 Neural Cell Adhesion Molecule 1 Neuron development 
S100B S100 Calcium Binding Protein B Astrocytosis 
EAAT2 Solute Carrier Family 1 Glial glutamate transporter 
GFAP Glial Fibrillary Acidic Protein 
Mature astrocyte intermediate 
filament 
MBP Myelin Basic Protein 
Constituent of myelin sheath of 
oligodendrocyte 
